You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Intensive chemotherapy is the foundation of treatment for adults with secondary AML subtypes, such as t-AML or AML-MRC1,2

VYXEOS demonstrated superior overall survival and a better chance to reach HSCT vs 7+33,a

Median overall survival was 9.6 months for VYXEOS vs 5.9 months for 7+3 (P=0.005; HR=0.69 [0.52, 0.90]) in a Phase 3 trial. Overall rate of HSCT was 34% for VYXEOS vs 25% for 7+3.3,b

Phase 3 randomized, multicenter, open-label, active-controlled study of VYXEOS vs cytarabine and daunorubicin (7+3) in patients 60 to 75 years of age with newly-diagnosed t-AML or AML-MRC.3 See full study design

Husband and wife at garden center inside VYXEOS (daunorubicin and cytarabine) liposome

Intensive chemotherapy is the foundation of treatment for adults with secondary AML subtypes, such as t-AML or AML-MRC1,2

VYXEOS demonstrated superior overall survival and a better chance to reach HSCT vs 7+33,a

Secondary AML subtypes

Identifying and diagnosing t-AML and AML-MRC

Learn more

Video library

Featuring healthcare professionals and patients talking about VYXEOS

Watch now

NCCN recommendations

NCCN recommendations for liposomal daunorubicin and cytarabine (VYXEOS)

Explore

Median overall survival was 9.6 months for VYXEOS vs 5.9 months for 7+3 (P=0.005; HR=0.69 [0.52, 0.90]) in a Phase 3 trial. Overall rate of HSCT was 34% for VYXEOS vs 25% for 7+3.3,b

Phase 3 randomized, multicenter, open-label, active-controlled study of VYXEOS vs cytarabine and daunorubicin (7+3) in patients 60 to 75 years of age with newly-diagnosed t-AML or AML-MRC.3 See full study design

checkmark icon

CMS approves new technology add-on payment for VYXEOS

VYXEOS meets the definition of newness, substantial clinical improvement relative to existing therapies, and cost thresholds. Contact your Jazz Access and Reimbursement Manager (ARM) for more information.

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.